Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 11

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 11
---
 rights with respect to any founder
shares, private shares and public shares held by them in connection with a shareholders’ vote to amend the amended and restated
memorandum and articles of association (A) to modify the substance or timing of the obligation to allow redemption in connection
with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete the initial Business Combination
within the Combination Period (as defined below) or (B) with respect to any other material provisions relating to shareholders’
rights or pre-initial business combination activity; and (iii) waive their rights to liquidating distributions from the trust account
with respect to any founder shares and private shares they hold if the Company fails to complete the initial Business Combination within
the Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public
shares they hold if the Company fails to complete the initial Business Combination within the Combination Period). If the Company submits
the initial Business Combination to the public shareholders for a vote, the initial shareholders, directors and officers have agreed
(and their permitted transferees will agree), pursuant to the terms of a letter agreement, to vote any shares held by them in favor of
the initial Business Combination.

6

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

The
underwriters have agreed to waive their rights to their deferred underwriting commissions (see Note 6) held in the Trust Account
in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will
be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the
event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than
the Initial Public Offering price per Unit ($10.00).

The
Company will have until 15 months from the closing of the Initial Public Offering (April 29, 2026) to complete a Business Combination.
However, if the Company is unable to complete the initial Business Combination within 15 months from the closing the Initial Public
Offering, the time period to complete an initial Business Combination can be extended without shareholder approval up to two times, each
by an additional three months (for a